

Journal Pre-proof

The Independent Impact of Peripheral Arterial Disease on Mortality in Nonagenarians and Centenarians Who Were Treated in an Intensive Care Unit: A Consecutive Cohort of 1 108 Patients

Kevin Roedl, Rikus Daniels, Pauline Theile, Stefan Kluge, Jakob Müller, Christian-Alexander Behrendt

PII: S1078-5884(23)00060-6

DOI: <https://doi.org/10.1016/j.ejvs.2023.01.026>

Reference: YEJVS 8648

To appear in: *European Journal of Vascular & Endovascular Surgery*

Received Date: 1 July 2022

Revised Date: 18 November 2022

Accepted Date: 13 January 2023

Please cite this article as: Roedl K, Daniels R, Theile P, Kluge S, Müller J, Behrendt C-A, The Independent Impact of Peripheral Arterial Disease on Mortality in Nonagenarians and Centenarians Who Were Treated in an Intensive Care Unit: A Consecutive Cohort of 1 108 Patients, *European Journal of Vascular & Endovascular Surgery*, <https://doi.org/10.1016/j.ejvs.2023.01.026>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2023 The Author(s). Published by Elsevier B.V. on behalf of European Society for Vascular Surgery.



1 The Independent Impact of Peripheral Arterial Disease on Mortality in Nonagenarians and
2 Centenarians Who Were Treated in an Intensive Care Unit: A Consecutive Cohort of 1 108
3 Patients

4

5 Kevin Roedl^a, Rikus Daniels^a, Pauline Theile^a, Stefan Kluge^a, Jakob Müller^{a,b,‡}, and Christian-
6 Alexander Behrendt^{c,‡,*}

7

8 ^a Department of Intensive Care Medicine, University Medical Centre Hamburg-Eppendorf,
9 Hamburg, Germany

10 ^b Department of Anaesthesiology, Tabea Hospital, Hamburg, Germany

11 ^c Department of Vascular Medicine, University Heart and Vascular Centre UKE Hamburg,
12 University Medical Centre Hamburg-Eppendorf, Hamburg, Germany

13

14 [‡] Jakob Müller and Christian-Alexander Behrendt contributed equally.

15

16 * Corresponding author. Department of Vascular Medicine, University Heart and Vascular
17 Centre UKE Hamburg, University Medical Centre Hamburg-Eppendorf, Martinistraße 52,
18 20246 Hamburg, Germany.

19 behrendt@hamburg.de

20

21 **WHAT THIS PAPER ADDS**

22 In this large up to date consecutive cohort of 1 108 critically ill nonagenarians and
23 centenarians treated in an intensive care unit between 1 January 2008 and 30 April 2019, a
24 total of 24% were diagnosed with any peripheral arterial disease (PAD). For the first time, the
25 independent impact of PAD on short term and long term mortality was determined while PAD
26 outweighed the effect of higher age in this study population. Forty one per cent of the patients
27 with PAD died during the hospital stay (vs. 26% in a comparison group, hazard ratio 1.97, $p <$
28 .001).

29

30 **Objective:** To investigate the clinical characteristics, risk factors, and outcomes of inpatients
31 with peripheral arterial disease (PAD) including lower extremity PAD, abdominal aortic
32 aneurysm (AAA), and carotid artery disease in a large cohort of critically ill patients aged \geq
33 90 years.

34 **Methods:** A retrospective analysis was conducted of all adult patients aged ≥ 90 years
35 consecutively admitted to the intensive care unit at a tertiary care centre in Hamburg,
36 Germany, between 1 January 2008 and 30 April 2019. Multivariable regression and Kaplan–
37 Meier methods were used to determine the independent impact of PAD on short term and long
38 term mortality endpoints. The analyses were adjusted for confounding by several
39 sociodemographic and clinical parameters including Charlson Comorbidity Index (CCI) and
40 established clinical risk scores.

41 **Results:** A total of 1 108 eligible patients were identified (92.3 years, 33% men). Of these,
42 24% had PAD (9% lower extremity PAD, 2% AAA, 15% coronary artery disease) and 76%
43 did not have any history of PAD and were used as a comparison group. When compared with
44 the comparison group, patients with PAD had a higher CCI (2 vs. 1, $p < .001$), more often
45 chronic kidney disease (28% vs. 21%, $p = .019$), and renal replacement therapy (5% vs. 2%, p
46 = .016). Furthermore, they needed vasopressors (48% vs. 40%, $p = .027$) and parenteral
47 nutrition (10% vs. 6%, $p = .041$) more often. After adjusting for confounding, PAD was
48 independently associated with increased in hospital (hazard ratio [HR] 1.97, 95% confidence
49 interval [CI] 1.39 – 2.81, $p < .001$) and long term mortality (HR 1.32, 95% CI 1.05 – 1.66, $p =$
50 .019).

51 **Conclusion:** One out of four critically ill nonagenarians and centenarians in an ICU in
52 Germany had PAD. PAD was associated with both higher short and long term mortality while
53 its impact outweighed higher age. Future studies should address this increasingly important
54 population beyond 89 years of age.

55
56 **Keywords:** Critical illness, Critically ill, Intensive care unit, Nonagenarians, Peripheral
57 vascular disease, Vascular disease, Very elderly

58 59 <H1>INTRODUCTION

60 Due to improvements in preventive medicine, medical innovations, and best medical
61 treatment, the life expectancy of global populations has increased rapidly. The population of
62 very old patients is expected to grow further; there will be over 30 million people who are 90
63 years or older (nonagenarian, centenarian) by 2030.¹ To date, about 15% of critically ill
64 patients in the intensive care unit (ICU) are aged ≥ 80 years and 1% are aged ≥ 90 years.^{2,3}

65 Peripheral arterial disease (PAD) including lower extremity PAD, carotid artery
66 disease, and abdominal aortic aneurysm (AAA), is a common manifestation of systemic
67 atherosclerosis.^{4–8} In 2015, almost 237 million patients were affected by PAD worldwide with

68 an increasing prevalence of approximately 15–20% in patients aged between 70 and 74 years,
69 and further increasing prevalence with age.^{4,9} Especially in octogenarians and nonagenarians
70 there are data suggesting an increasing prevalence of PAD with more than 20% having PAD
71 in at least one arterial territory.¹⁰ According to the World Health Organization (WHO) and
72 national death statistics, PAD is among the three most common causes of death, which
73 emphasizes the burden of this common disease. Despite this, the impact of PAD on outcomes
74 in patients aged over 90 years remains understudied, especially when focusing on inpatients
75 requiring advanced treatment in an ICU.

76 This study aimed to investigate the clinical characteristics, risk factors, and outcomes
77 of inpatients with PAD in a large cohort of critically ill patients aged ≥ 90 years in a tertiary
78 care university hospital.

79 <H1>METHODS

80 <H2>Study design, setting, and ethics

81 Data of all adult nonagenarians (90 – 99 years) and centenarians (≥ 100 years) consecutively
82 admitted to the Department of Intensive Care Medicine at the University Medical Centre
83 Hamburg-Eppendorf (Hamburg, Germany) between 1 January 2008 and 30 April 2019, were
84 retrospectively analysed. The department covers 12 intensive care wards and provides health
85 benefits for all critically ill adult (≥ 18 years) patients of the university hospital with a total
86 capacity of 140 beds. The Ethics Committee of the Hamburg Chamber of Physicians was
87 informed about the study (No.: 2022-300219-WF). Due to the retrospective nature of the
88 study and the de-identified study data, the need for explicit informed consent was waived.
89 Information regarding mortality up to one year was obtained from the national death register
90 of Germany at least one year after admission to ICU.

91 <H2>Inclusion and exclusion criteria

92 All consecutively treated inpatients aged ≥ 90 years who were admitted to the ICU were
93 included in the study. Patients < 90 years of age and patients with incomplete clinical data (n
94 = 17, 1.5%) were excluded (Fig. 1).

95 <H2>Data collection

96 Data was collected through a digital patient data management system (PDMS, Integrated Care
97 Manager (ICM), Version 9.1 – Draeger Medical, Lubeck, Germany). The extracted data
98 included age in years, dichotomised sex, comorbidities according to the Charlson
99 Comorbidity Index (CCI), primary admission diagnosis (medical, surgical – elective, surgical
100 – emergency; the term surgical refers to all surgical procedures), total length of ICU and
101 hospital stay in days, survival during ICU and hospital stay, treatment modalities and organ

102 support (mechanical ventilation, vasopressor, renal replacement therapy, blood transfusions,
103 applied antibiotics, applied antivirals), and routine laboratory parameters. Routine laboratory
104 assessment was performed on a daily basis within clinical routine.

105 <H2>Study definitions and patient management

106 All data were derived retrospectively. The variable PAD included the entities 1) PAD of the
107 lower extremities usually diagnosed by an ankle brachial index (ABI) ≤ 0.9 or any reported
108 history of intermittent claudication or chronic limb threatening ischaemia;¹¹ 2) usually
109 diagnosed by an infrarenal aortic diameter ≥ 3.0 cm or any reported history of an AAA;¹² 3)
110 carotid artery disease usually defined by any diagnosis of an intimal media thickness of ≥ 1.0
111 mm or reported history of carotid artery plaques.^{13,14}

112 Severity of illness was evaluated by Sequential Organ Failure Assessment (SOFA)¹⁵
113 and Simplified Acute Physiology (SAPS II)¹⁶ score on admission. The CCI¹⁷ was calculated
114 in all patients. Sepsis and septic shock were defined according to the 2016 Third International
115 Consensus Definition for Sepsis and Septic Shock.¹⁸

116 <H2>Statistical analysis

117 Data are presented as absolute numbers and relative frequency or median and interquartile
118 range (IQR). Categorical variables were compared via chi-square analysis or Fisher's exact
119 test, as appropriate. Continuous variables were compared via Mann–Whitney U test or
120 Student *t* test, as appropriate. Factors associated with PAD and mortality were clinically
121 assessed. A multivariable logistic regression with PAD as the dependent variable and clinical
122 variables as covariables was used. A multivariable Cox proportional hazards model was used
123 to estimate the effect of PAD on in hospital and midterm survival.

124 In both models, a stepwise backward elimination approach was used that gradually
125 reduces the initial model; variables that caused a change in estimates $> 10\%$ remained in the
126 model. Survival function estimates were calculated using the Kaplan–Meier method and were
127 compared by the log rank test. Further, a landmark analysis was performed for long term
128 outcomes excluding all patients dying in hospital. Patients alive at the landmark point were
129 categorised PAD and non-PAD. A sensitivity analysis was run with the hospital surviving
130 patients included in the PAD along with the patients who had non-PAD. Statistical analysis
131 was conducted using IBM SPSS Statistics Version 24.0 (IBM Corp., Armonk, NY, USA). A *p*
132 value $< .050$ was considered statistically significant. No correction was applied for multiple
133 hypothesis testing. A complete case exclusion was applied for missing variables. The study
134 was prepared in accordance with the STROBE (STrengthening the Reporting of
135 OBservational studies in Epidemiology) recommendations.¹⁹

136 <H1>RESULTS

137 <H2>Baseline characteristics of the study population

138 During the study period from 1 January 2008 to 30 April 2019, a total number of 92 958
139 patients were treated at the study centre ICU. Overall, 1.2% (1 108/92 958) were aged > 89
140 years and were included in the study (Fig. 1). From the total cohort, 24% of patients ($n = 264$)
141 were identified with PAD and 76% ($n = 844$) without PAD. In terms of vascular diseases,
142 coronary artery disease was observed in 15% of patients ($n = 171$), lower extremity PAD in
143 9% ($n = 101$), and AAA in 2% ($n = 24$).

144 <H2>Comparison of clinical characteristics in patients with versus without peripheral 145 arterial disease (crude comparison)

146 The baseline characteristics of patients with versus without PAD are shown in Table 1.
147 Demographic characteristics including age, sex, and BMI were comparable in both strata.
148 Primary admission cause to the ICU was medical (34% for PAD vs. 34%, $p = .95$), elective
149 surgery (29% for PAD vs. 39%, $p = .003$), and emergency surgery (36% for PAD vs. 26%, $p =$
150 $.003$). The CCI was 2 (IQR 1, 3) in median compared with 1 (IQR 0, 2) points in patients with
151 and without PAD ($p < .001$), respectively. Detailed characteristics on comorbidities are shown
152 in Supplementary Table S1. Patients with PAD had comparable disease severity on
153 admission, represented by SAPS II (38 vs. 36 points, $p = .22$), SOFA (3 vs. 2 points, $p = .13$)
154 on admission and after 24 hours (2 vs. 2 points, $p = .069$). Patients with PAD were
155 mechanically ventilated in 37% ($n = 97$) compared with 35% ($n = 292$) in those without PAD
156 ($p = .52$). Thereby, the duration of MV was 0.7 (IQR 0.27, 1.38) and 0.5 (IQR 0.18, 1.17)
157 days in patients with and without PAD, respectively ($p = .11$). Vasopressor therapy (48% vs.
158 40%, $p = .027$), renal replacement therapy (5% vs. 2%, $p = .016$), and parenteral nutrition
159 (10% vs. 6%, $p = .041$) was more frequent in patients with PAD. Tracheostomy (2% vs. 1%, p
160 $= .66$) was observed similarly in both groups. The requirement of transfusion of red blood
161 cells, thrombocytes, or fresh frozen plasma was comparable in both groups. Further, detailed
162 laboratory and blood gas analysis characteristics are shown in Table 1.

163 <H2>Outcomes of patients with versus without peripheral arterial disease (crude 164 comparison)

165 The median stay of the entire cohort in the ICU and hospital was 1.6 (IQR 0.9, 3.5) and 11
166 (IQR 7, 16.6) days, respectively. Overall, 18% ($n = 201$) died in the ICU and 30% ($n = 331$)
167 during the hospital stay. During the ICU stay, 23% ($n = 62$) of the patients with PAD died (vs.
168 16%, $n = 139$, without PAD, $p = .010$). During the total in hospital stay, 41% ($n = 108$) of the
169 patients with PAD died (vs. 26%, $n = 223$, $p < .001$). The median length of stay at the ICU

170 and in the hospital was 1.7 (IQR 0.9, 4.1) and 11.1 (IQR 5.9, 17.2) days in patients with PAD
171 and 1.5 (IQR 0.9, 3.2) and 11.0 (IQR 7.0, 16.5) in patients without PAD, respectively.

172 The Kaplan–Meier survival estimates including long term follow up are depicted in
173 Fig. 2. The sensitivity analysis regarding the effect of PAD on mortality (Landmark analysis)
174 was confirmative (Supplementary Fig. S1).

175 Patients who survived the hospital stay ($n = 777$) were discharged to their home in
176 28% ($n = 28$) with PAD and without PAD 25% ($n = 153$) ($p = .077$), nursing facility in 27%
177 ($n = 42$) and 15% ($n = 91$) ($p < .001$), rehabilitation facility in 41% ($n = 64$) and 45% ($n =$
178 282) ($p = .33$), and another hospital in 13% ($n = 21$) and 15% ($n = 95$) ($p = .57$). The
179 discharge destination was unknown for one patient.

180 <H2>Logistic and Cox regression analysis for factors associated with in hospital and 30 181 day mortality

182 Multivariate regression analysis identified PAD (odds ratio [OR] 1.973, 95% confidence
183 interval [CI] 1.387 – 2.808; $p < .001$) as an independent factor associated with short term
184 mortality during the hospital stay. The Cox regression analysis identified PAD (hazard ratio
185 [HR] 1.316, 95% CI 1.046 – 1.656; $p = .019$) as an independent factor associated with long
186 term mortality (Tables 2 and 3).

187 <H1>DISCUSSION

188 In this large consecutive cohort of critically ill nonagenarians and centenarians who were
189 treated at a tertiary care ICU in Germany, one out of four patients suffered from PAD. When
190 compared with the comparison group, these patients underwent emergency surgery more
191 often, had a higher comorbidity index, were more often dialysis dependent, and died more
192 often during both the ICU and hospital stay. After adjusting for confounding, the
193 atherosclerotic disease burden contributed substantially to worse outcomes when compared
194 with very old patients without co-existing PAD. Moreover, the impact of peripheral
195 atherosclerosis outweighed higher age in this study population.

196 According to data from the Organisation for Economic Co-Operation and
197 Development (OECD), the population-based life expectancy at birth increased by
198 approximately 11 years from 69.7 in 1970 to 81.0 in 2019. As of today, ICU patients aged \geq
199 90 years represent a rapidly growing population while approximately 64% of these patients
200 are in need of long term care.²⁰

201 Cardiovascular diseases comprise a heterogeneous group of chronic progressive
202 conditions that are the leading cause of death globally. Patients with PAD and especially those
203 with multisite artery disease face devastating outcomes during the hospital stay and beyond.⁶

204 In recent registry cohorts, the five year amputation and death rates reached 13 – 50% in
205 patients with intermittent claudication and 50 – 90% in patients with chronic limb threatening
206 ischaemia.^{21–23} Thereby, data derived from the Global Burden of Disease study emphasised
207 that the age specific PAD death rate increased markedly with age, particularly in patients aged
208 ≥ 80 years also over time.²⁴

209 Against this background it appears interesting that recent practice guidelines on
210 vascular disease did not comprehensively cover the management of this increasingly relevant
211 population.^{6,25} A possible explanation for this is that only very few studies specifically
212 addressed populations aged > 89 years.

213 In a two centre retrospective observational study of acute ischaemic stroke patients
214 who underwent mechanical thrombectomy, only 7% were aged 90 – 99 years but the
215 outcomes were comparable with those of octogenarians. The authors concluded that it did not
216 appear justifiable to withhold invasive therapy, although the absolute treatment effect among
217 nonagenarians remained unknown.²⁶ In another retrospective review of 32 421 patients who
218 underwent open heart surgery, only 0.4% were nonagenarians. When compared with
219 octogenarians, the nonagenarians exhibited similar mortality and complication rates during
220 the hospital stay.²⁷ This finding, however, was contrasted by results from interventional aortic
221 valve therapy in which 19% of patients were aged 90 – 99 years. While major vascular
222 complications and in hospital mortality rate were higher in nonagenarians, the overall
223 technical success was high and comparable with that of younger cohorts.²⁸ Siam *et al.* used a
224 large database from an academic centre to determine factors associated with outcomes of
225 surgery in patients aged ≥ 90 years. Between 2014 and 2018, 198 nonagenarians were
226 included (38% elective). Emphasised by considerably low mortality rates after elective
227 surgery, the authors concluded that surgery can be safely performed with acceptable two year
228 outcomes, but emergency surgery for oncology carried rather dismal outcomes.²⁹

229 In terms of PAD, the existing evidence base remains limited to very few observational
230 cohorts. Casajuana Urgell *et al.* used a single centre institutional database covering 171
231 nonagenarians with chronic limb threatening ischaemia who were treated between 2005 and
232 2019. Almost one third of the patients had a direct indication for amputation or palliative care
233 at presentation. Besides higher age (> 92 years), a low haemoglobin level, congestive heart
234 failure, non-severe dementia, and limited mobility (wheelchair) were associated with worse
235 survival.³⁰ Kumar *et al.* used data derived from the National Surgical Quality Improvement
236 Program (NSQIP) dataset in the United States to determine outcomes in patients aged ≥ 90
237 years who had undergone abdominal aortic aneurysm repair from 2005 to 2017. Among 1 356

238 patients, 91% had undergone endovascular repair and 9% open surgery. The overall 30 day
239 mortality was only 10.4% while nonagenarians had an incrementally increased, but
240 acceptable, risk with EVAR in elective and emergent cases compared with that reported for
241 octogenarians and cohorts not selected for age. Dependent status, higher American Society of
242 Anaesthesiologists (ASA) classification, emergent repair, and open surgery were associated
243 with mortality.³¹

244 The current study results may help to extend the limited knowledge by including a
245 very old and critically ill population to determine the complex interaction between age and
246 PAD. In line with previous cohorts, nonagenarians and centenarians had markedly high
247 mortality rates during the ICU and hospital stay that were comparable with those of patients
248 who were treated at ICU units after out of hospital cardiac arrest.^{32,33}

249 Interestingly, while the overall risk profile and certain parameters were broadly similar
250 between both comparison groups, the diagnosis of PAD was clearly associated with higher
251 short and long term mortality in multivariable regression models. Especially during the
252 hospital stay, the impact of PAD outweighed higher age and established comorbidity indices
253 while landmark analyses emphasised that the association between PAD and long term
254 mortality rates was less robust. It appears important to note that 15% of the patients had
255 coronary artery disease. Systemic atherosclerosis affects different vascular beds and affects
256 end organ microcirculation and perfusion in a multifactorial manner.

257 Besides its strengths, the current study has also limitations. Firstly, the non-
258 randomised study design led to the possibility that residual confounding may have affected
259 the relationship between the index diseases and outcomes of interest. This remains an
260 unsolved challenge of observational research in general, but robust methods were applied and
261 comorbidity indices established to reduce the inherent risk. Furthermore, the inclusion of a
262 hospitalised cohort introduces a possible selection bias. The generalisability of the current
263 study findings to non-hospitalised elderly remains unknown until further studies test the
264 generated hypotheses on outpatient populations. Unfortunately, it is commonly known that
265 prospective epidemiological cohorts and screening studies seldomly enrol participants aged >
266 80 years. Secondly, although the current study could only include data from a single centre,
267 the intensive care department comprised a total of 140 beds and all medical specialties at a
268 tertiary care centre in a large metropolitan area. Thirdly, the detection of the index diseases
269 depended on various factors, and it could not be ruled out that undiagnosed PAD impaired the
270 models. However, it appears rather unlikely that inpatients aged > 89 years have never been
271 diagnosed for these chronic conditions in either systematic or opportunistic screening

272 examinations. Lastly, although of increasing interest, the current study could not cover the
273 complex relationship between patient frailty and poor outcomes.

274 Considering the current study findings, it appears reasonable to propose increased
275 awareness among intensive care physicians and nurses to underline the potential impact of
276 PAD and multisite artery disease on morbidity and mortality. Likewise, future studies are
277 needed to expand the limited knowledge about this increasingly important population of very
278 old patients with critical illness. While both intensive care and health services research
279 entered the digital era long ago, it appears possible to use the rapidly growing information and
280 sophisticated big data analytics to identify those who are in need of exceedingly intensive
281 care. This explorative study may generate the first hypotheses to launch further projects.

282 <H2>Conclusion

283 In this large consecutive single centre database on 1 108 critically ill nonagenarians and
284 centenarians on an ICU in Germany, one out of four patients had PAD. The diagnosis of any
285 PAD was associated with both higher short and long term mortality while its impact
286 outweighed higher age. Future studies should address this increasingly important population
287 aged > 89 years.

288 CONFLICT OF INTEREST

289 P.T., R.D., J.M. and C.-A.B. do not report any conflicts of interest. S.K. received research
290 support from Ambu, E.T.View Ltd, Fisher & Paykel, Pfizer, and Xenios, lecture honoraria
291 from ArjoHuntleigh, Astellas, Astra, Basilea, Bard, Baxter, Biotest, CSL Behring,
292 CytoSorbents, Fresenius, Gilead, MSD, Orion, Pfizer, Philips, Sedana, Sorin, Xenios, and
293 Zoll, and consultant honorarium from AMOMED, Astellas, Baxter, Bayer, Fresenius, Gilead,
294 MSD, Pfizer and Xenios. K.R. received travel support from Gilead, and reports no other
295 potential conflict of interest relevant to this article.

296 FUNDING

297 This study was supported exclusively by institutional funds of the Department of Intensive
298 Care Medicine.

299 REFERENCES

- 300 1. Kontis V, Bennett JE, Mathers CD, Li G, Foreman K, Ezzati M. Future life
301 expectancy in 35 industrialised countries: projections with a Bayesian model ensemble.
302 *Lancet* 2017;**389**:1323–35.
- 303 2. Nielsson MS, Christiansen CF, Johansen MB, Rasmussen BS, Tønnesen E, Nørgaard
304 M. Mortality in elderly ICU patients: a cohort study. *Acta Anaesthesiol Scand* 2014;**58**:19–26.

- 305 3. Becker S, Muller J, de Heer G, Braune S, Fuhrmann V, Kluge S. Clinical
306 characteristics and outcome of very elderly patients ≥ 90 years in intensive care: a
307 retrospective observational study. *Ann Intensive Care* 2015;**5**:53.
- 308 4. Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, et al. Global, regional,
309 and national prevalence and risk factors for peripheral artery disease in 2015: an updated
310 systematic review and analysis. *Lancet Glob Health* 2019;**7**:e1020–30.
- 311 5. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al.
312 Comparison of global estimates of prevalence and risk factors for peripheral artery disease in
313 2000 and 2010: a systematic review and analysis. *Lancet* 2013;**382**:1329–40.
- 314 6. Aboyans V, Ricco JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T, et al.
315 Editor's Choice - 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial
316 Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). *Eur J*
317 *Vasc Endovasc Surg* 2018;**55**:305–68.
- 318 7. Song P, Fang Z, Wang H, Cai Y, Rahimi K, Zhu Y, et al. Global and regional
319 prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-
320 analysis, and modelling study. *Lancet Glob Health* 2020;**8**:e721–9.
- 321 8. Wanhainen A, Verzini F, Van Herzelee I, Allaire E, Bown M, Cohnert T, et al.
322 Editor's Choice - European Society for Vascular Surgery (ESVS) 2019 Clinical Practice
323 Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms. *Eur J Vasc*
324 *Endovasc Surg* 2019;**57**:8–93.
- 325 9. Diehm C, Schuster A, Allenberg JR, Darius H, Haberl R, Lange S, et al. High
326 prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients:
327 cross-sectional study. *Atherosclerosis* 2004;**172**:95–105.
- 328 10. Savji N, Rockman CB, Skolnick AH, Guo Y, Adelman MA, Riles T, et al. Association
329 between advanced age and vascular disease in different arterial territories: a population
330 database of over 3.6 million subjects. *J Am Coll Cardiol* 2013;**61**:1736–43.
- 331 11. Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, et al.
332 Measurement and Interpretation of the Ankle-Brachial Index. *Circulation* 2012;**126**:2890–
333 909.
- 334 12. Wanhainen A, Verzini F, Van Herzelee I, Allaire E, Bown M, Cohnert T, et al.
335 Editor's Choice - European Society for Vascular Surgery (ESVS) 2019 Clinical Practice
336 Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms. *Eur J Vasc*
337 *Endovasc Surg* 2019;**57**:8–93.

- 338 13. Naylor AR, Rantner B, Ancetti S, de Borst GJ, De Carlo M, Halliday A, et al.
339 European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the
340 Management of Atherosclerotic Carotid and Vertebral Artery Disease. *Eur J Vasc Endovasc*
341 *Surg* 2023;**65**:7–111.
- 342 14. Jagodzinski A, Johansen C, Koch-Gromus U, Aarabi G, Adam G, Anders S, et al.
343 Rationale and design of the Hamburg City Health Study. *Eur J Epidemiol* 2020;**35**:169–81.
- 344 15. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The
345 SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure.
346 On behalf of the Working Group on Sepsis-Related Problems of the European Society of
347 Intensive Care Medicine. *Intensive Care Med* 1996;**22**:707–10.
- 348 16. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score
349 (SAPS II) based on a European/North American multicenter study. *JAMA* 1993;**270**:2957–63.
- 350 17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
351 prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*
352 1987;**40**:373–83.
- 353 18. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al.
354 The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*
355 2016;**315**:801–10.
- 356 19. von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP, et al.
357 The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
358 statement: guidelines for reporting observational studies. *J Clin Epidemiol* 2008;**61**:344–9.
- 359 20. OECD. Life expectancy at 65 (indicator). Available at: [https://www.oecd-](https://www.oecd-ilibrary.org/social-issues-migration-health/life-expectancy-at-65/indicator/english_0e9a3f00-en)
360 [ilibrary.org/social-issues-migration-health/life-expectancy-at-65/indicator/english_0e9a3f00-](https://www.oecd-ilibrary.org/social-issues-migration-health/life-expectancy-at-65/indicator/english_0e9a3f00-en)
361 [en](https://www.oecd-ilibrary.org/social-issues-migration-health/life-expectancy-at-65/indicator/english_0e9a3f00-en) [Accessed on 6 June 2020].
- 362 21. Kreutzburg T, Peters F, Kuchenbecker J, Marschall U, Lee R, Kriston L, et al. Editor's
363 Choice - The GermanVasc Score: A Pragmatic Risk Score Predicts Five Year Amputation
364 Free Survival in Patients with Peripheral Arterial Occlusive Disease. *Eur J Vasc Endovasc*
365 *Surg* 2021;**61**:248–56.
- 366 22. Baubeta Fridh E, Andersson M, Thuresson M, Sigvant B, Kragsterman B, Johansson
367 S, et al. Amputation rates, mortality, and pre-operative comorbidities in patients
368 revascularised for intermittent claudication or critical limb ischaemia: a population based
369 study. *Eur J Vasc Endovasc Surg* 2017;**54**:480–6.

- 370 23. Sartipy F, Sigvant B, Lundin F, Wahlberg E. Ten year mortality in different peripheral
371 arterial disease stages: a population based observational study on outcome. *Eur J Vasc*
372 *Endovasc Surg* 2018;**55**:529–36.
- 373 24. Sampson UK, Fowkes FG, McDermott MM, Criqui MH, Aboyans V, Norman PE, et
374 al. Global and regional burden of death and disability from peripheral artery disease: 21 world
375 regions, 1990 to 2010. *Glob Heart* 2014;**9**:145–58 e21.
- 376 25. Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. Global
377 Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. *Eur J Vasc*
378 *Endovasc Surg* 2019;**58**:S1–S109 e33.
- 379 26. Hendrix P, Killer-Oberpfalzer M, Broussalis E, Melamed I, Sharma V, Mutzenbach S,
380 et al. Outcome following mechanical thrombectomy for anterior circulation large vessel
381 occlusion stroke in the elderly. *Clin Neuroradiol* 2022;**32**:369–74.
- 382 27. Elsisy MF, Schaff HV, Crestanello JA, Alkhouli MA, Stulak JM, Stephens EH.
383 Outcomes of cardiac surgery in nonagenarians. *J Card Surg* 2022;**37**:1664–70.
- 384 28. Matta A, Lhermusier T, Bouisset F, Parada FC, M EL, Nader V, et al. Outcomes of
385 transcatheter aortic valve implantation in nonagenarians compared to younger than 90 year
386 old patients. *Am J Med* 2022;**135**:745–51.
- 387 29. Siam B, Cooper L, Orgad R, Esepkina O, Kashtan H. Outcomes of surgery in patients
388 90 years of age and older: a retrospective cohort study. *Surgery* 2022;**171**:1365–72.
- 389 30. Casajuana Urgell E, Calsina Juscafresa L, Nieto Fernandez L, Romero Montaña L,
390 Llorc Pont C, Clarà Velasco A. Critical limb ischemia in nonagenarians: a challenge of our
391 times. *World J Surg* 2022;**46**:2825–31.
- 392 31. Kumar M, Long GW, Major M, Gates E, Studzinski DM, Callahan RE, et al.
393 Predictors of mortality in nonagenarians undergoing abdominal aortic aneurysm repair:
394 Analysis of the National Surgical Quality Improvement Program dataset. *J Vasc Surg*
395 2022;**75**:1223–33.
- 396 32. Bruno RR, Wernly B, Kelm M, Boumendil A, Morandi A, Andersen FH, et al.
397 Management and outcomes in critically ill nonagenarian versus octogenarian patients. *BMC*
398 *Geriatr* 2021;**21**:576.
- 399 33. Pätz T, Stelzig K, Pfeifer R, Thiele H, Busch HJ, Stiermaier T, et al. Sex-specific
400 differences and outcome in elderly patients after survived out-of-hospital cardiac arrest. *Med*
401 *Klin Intensivmed Notfmed* 2022;**117**:630–8.

403 **Figure 1.** Flowchart of the study to investigate the clinical characteristics, risk factors, and
 404 outcomes of 1 108 critically ill nonagenarians, 264 with and 844 without peripheral arterial
 405 disease (PAD), at a tertiary care centre in Hamburg, Germany, between 1 January 2008 and
 406 30 April 2019. ICU = intensive care unit.

407

408 **Figure 2.** Kaplan–Meier survival estimates stratified according to the presence of peripheral
 409 arterial disease (PAD); follow up information was missing for 18 patients (1.6%).

410

411

412

Table 1. Characteristics of 1 108 patients, 264 with and 844 without peripheral arterial disease (PAD), intensive care unit (ICU) at a tertiary care centre in Hamburg, Germany, between 1 January 2008 and 30 April 2019.

Variables	All (n = 1 108)	PAD (n = 264)	Non-PAD (n = 844)
Age – y	92.3 (91.0, 94.2)	92.4 (91.2, 94.4)	92.2 (90.9, 94.1)
Men	361 (33)	87 (33)	274 (31)
Median BMI – kg/m ²	23.4 (21.0, 25.9)	23.9 (21.3, 26.2)	23.4 (20.9, 25.9)
<i>Primary admission</i>			
Medical	376 (34)	90 (34)	286 (34)
Elective surgery	409 (37)	77 (29)	332 (39)
Emergency surgery	316 (29)	94 (36)	222 (26)
<i>Disease severity</i>			
SAPS II, admission	36 (28, 47)	38 (28, 47)	36 (28, 47)
SOFA, admission	2 (1, 5)	3 (1, 6)	2 (1, 5)
SOFA, 24 h	2 (1, 4)	2 (1, 5)	2 (1, 4)
<i>Comorbidities</i>			
Charlson Comorbidity Index	1 (0, 2)	2 (1, 3)	1 (0, 2)
Atrial fibrillation	427 (39)	110 (42)	317 (38)
Arterial hypertension	775 (70)	190 (72)	585 (69)
Chronic kidney disease	252 (23)	74 (28)	178 (21)
Coronary artery disease	170 (15)	40 (15)	130 (15)
Congestive heart failure	242 (22)	55 (21)	187 (22)
Diabetes	150 (14)	31 (12)	119 (14)
Chronic lung disease	89 (8)	21 (8)	68 (8)
<i>Respiratory support</i>			
Invasive MV	389 (35)	97 (37)	292 (35)
Duration of MV	0.5 (0.18, 1.24)	0.7 (0.27, 1.38)	0.5 (0.18, 1.17)

– d

<i>Procedures/therapies</i>			
Vasopressors	468 (42)	127 (48)	341 (40)
Renal replacement therapy	31 (3)	13 (5)	18 (2)
Parenteral nutrition	78 (7)	26 (10)	52 (6)
Cardiopulmonary resuscitation	82 (7)	22 (8)	60 (7)
Tracheostomy	14 (1)	4 (2)	10 (1)
Red blood cell transfusion	231 (21)	60 (23)	171 (20)
Thrombocyte transfusion	11 (1)	2 (1)	9 (1)
FFP transfusion	30 (3)	8 (3)	22 (3)
<i>Laboratory results at admission</i>			
Haemoglobin – g/dL	10.3 (9.2, 11.6)	10.3 (9.1, 11.5)	10.2 (9.2, 11.6)
Leukocytes – G/L	10.8 (8.0, 14.4)	10.8 (8.2, 14)	10.7 (7.8, 14.5)
Thrombocytes – G/L	208 (155, 272)	210 (159, 274)	207 (153, 269)
LDH – U/L	253 (208, 341)	252 (212, 332)	253 (107, 348)
Bilirubin – mg/dL	0.6 (0.4, 0.9)	0.6 (0.4, 0.9)	0.6 (0.4, 0.9)
CRP – mg/L	28 (8, 81)	31 (10, 82)	28 (7, 80)
Creatinine – mg/dL	1.1 (0.8, 1.6)	1.10 (0.84, 1.74)	1.10 (0.80, 1.60)
<i>Blood gas analysis</i>			
Lactate at admission – mmol/L	1.1 (0.8, 1.8)	1.1 (0.9, 1.9)	1.1 (0.8, 1.8)
pH at admission – level	7.37 (7.33, 7.42)	7.37 (7.31, 7.41)	7.38 (7.33, 7.42)
paO ₂ at admission – mmHg	92 (74, 131)	92 (72, 131)	93 (75, 131)
pH – level, lowest/nadir	7.36 (7.29, 7.43)	7.36 (7.28, 7.43)	7.36 (7.3, 7.42)
Lactate peak – mmol/L	1.7 (1.2, 2.7)	1.9 (1.3, 2.9)	1.7 (1.1, 2.6)
<i>Outcome</i>			
Duration of ICU stay – d	1.6 (0.9, 3.5)	1.7 (0.9, 4.1)	1.5 (0.9, 3.2)
Duration of hospital stay – d	11 (7, 16.6)	11.1 (5.9, 17.2)	11.0 (7.0, 16.5)
Died in ICU	201 (18)	62 (23)	139 (16)
Died in hospital	331 (30)	108 (41)	223 (26)

413 Data are expressed as *n* (%) or median (interquartile range – IQR 25/75%). *y* = years; BMI =

414 body mass index; SAPS = Simplified Acute Physiology Score; SOFA = Sequential Organ

415 Failure Assessment; h = hours; MV = mechanical ventilation; FFP = fresh frozen plasma;

416 LDH = lactate dehydrogenase; CRP = C reactive protein; paO₂ = partial pressure of O₂; d =
 417 day.

418

419

Table 2. Multivariable logistic regression for factors associated with short term mortality during the hospital stay of 1 108 patients, 264 with and 844 without peripheral arterial disease (PAD), aged ≥ 90 years at a tertiary care centre in Hamburg, Germany, between 1 January 2008 and 30 April 2019.*

Variables	OR (95% CI)	<i>p</i>
PAD	1.973 (1.387–2.808)	<.001
Primary admission – elective surgery	0.648 (0.447–0.940)	.022
SAPS II at admission	1.063 (1.048–1.078)	<.001
Mechanical ventilation during ICU	2.187 (1.535–3.117)	<.001
Vasopressors during ICU	1.954 (1.363–2.802)	<.001
Higher BMI (increase by kg/m ²)	0.593 (0.425–0.828)	<.001

420 OR = odds ratio; CI = confidence interval; PAD = peripheral arterial disease; SAPS =

421 Simplified Acute Physiology Score; ICU = intensive care unit; BMI = body mass index;

422 SOFA = Sequential Organ Failure Assessment.

423 * Variables included in the initial model: peripheral vascular disease, age, male sex, primary

424 admission – elective surgery, SAPS II at admission, Charlson Comorbidity Index, mechanical

425 ventilation during ICU, vasopressors during ICU, SOFA score, and BMI.

426

427

Table 3. Multivariable Cox proportional hazards model for factors associated with long term mortality of 1 108 patients, 264 with and 844 without peripheral arterial disease (PAD), aged ≥ 90 years at a tertiary care centre in Hamburg, Germany, between 1 January 2008 and 30 April 2019.*

Variables	HR (95 CI)	<i>p</i>
PAD	1.316 (1.046–1.656)	.019
Higher age (increase by 1 year)	1.040 (0.998–1.083)	.059
SAPS II at admission	1.057 (1.048–1.065)	<.001
Mechanical ventilation during ICU	1.517 (1.176–1.957)	.001

Vasopressors during ICU 1.424 (1.094–1.853) .009


428 HR = hazard ratio; CI = confidence interval; PAD = peripheral arterial disease; SAPS =
 429 Simplified Acute Physiology Score; ICU = intensive care unit; BMI = body mass index;
 430 SOFA = Sequential Organ Failure Assessment.

431 *Variables included in the initial model: peripheral vascular disease, age, male sex, primary
 432 admission – elective surgery, SAPS II at admission, Charlson Comorbidity Index, mechanical
 433 ventilation during ICU, catecholamines during ICU, SOFA score, and BMI.

434

435 Figures


436 Figure 1



437


438


439 Figure 2




440

441







EJVES18282

Short title: Peripheral Vascular Disease in Patients Aged 90 Years and Older

Figures

Figure 1, delete commas in thousands, use non-breaking space instead. Flowchart - see p. C1 of the 'EJVES instructions for typesetters' document.

Figure 2, delete hyphen in follow up. Kaplan-Meier - see pp. H1,H2 of the 'EJVES instructions for typesetters' document.

Supplementary material

EJVES18282_Supplementary Fig S1 and Table S1

Supplementary Figure S1. Kaplan–Meier survival estimates landmark analysis including all patients who survived the hospital stay stratified according to the presence of peripheral arterial disease (PAD); follow up information was missing for 18 patients (2.3%).

Supplementary Table S1. Pre-existing comorbidities with and without PAD.